Related Experiment Videos

Antibiotic treatment of children with secretory otitis media. A randomized, double-blind, placebo-controlled study

J Thomsen1, J Sederberg-Olsen, V Balle

  • 1Ear-Nose-Throat Department, Gentofte University Hospital, Hellerup, Denmark.

Insights

Amoxicillin-clavulanate potassium effectively treated secretory otitis media in children, improving tympanometry results significantly compared to placebo. This suggests antibiotics are a viable treatment before considering ventilating tubes.

Area of Science:

  • Pediatrics
  • Otolaryngology
  • Pharmacology

Background:

  • Secretory otitis media (SOM) is a common pediatric condition.
  • Current treatment guidelines for SOM often involve watchful waiting or tympanostomy tube insertion.
  • The efficacy of antibiotic treatment for SOM requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of amoxicillin-clavulanate potassium in treating children with secretory otitis media.
  • To compare the outcomes of antibiotic treatment versus placebo in children with SOM.

Main Methods:

  • A double-blind, randomized, placebo-controlled trial involving 264 children aged 1-10 years.
  • Participants received either amoxicillin-clavulanate potassium or placebo for one month.
  • Tympanometry was used to assess middle ear status at baseline, monthly during treatment, and for 12 months post-treatment.

Main Results:

  • 61% of children in the antibiotic group showed disease reversal compared to 30% in the placebo group (P < .0001).
  • The significant improvement in favor of antibiotics persisted for eight months post-treatment.
  • Middle ear status at the end of treatment predicted long-term outcomes, irrespective of initial treatment group.

Conclusions:

  • Amoxicillin-clavulanate potassium is effective in treating secretory otitis media in children.
  • Antibiotic therapy can improve tympanometric conditions, supporting its use before ventilating tube insertion.
  • The study highlights the potential of antibiotics as a first-line treatment for SOM.

Related Concept Videos